

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listings of Claims:

1-119. (Cancelled)

120. (Previously Presented) A method of increasing angiogenesis in a mammal comprising providing within or adjacent to tissue in need thereof in said mammal a therapeutically effective amount of Related Transcriptional Enhancer Factor-1 (RTEF-1) polypeptide or a nucleic acid molecule encoding said polypeptide, wherein said RTEF-1 polypeptide has at least 85% sequence identity to the sequence of SEQ ID NO: 7, and wherein said RTEF-1 polypeptide increases angiogenesis in said tissue of said mammal, relative to a mammal that is not administered said RTEF-1 polypeptide or said nucleic acid molecule encoding said polypeptide.

121. (Currently Amended) The method of claim 120, wherein said RTEF-1 polypeptide has at least 90% sequence identity to the sequence of SEQ ID NO:7SEQ ID NO:4.

122. (Previously Presented) The method of claim 120, wherein said RTEF-1 polypeptide is provided to said mammal by administering to said mammal a cell, tissue, or organ that contains said polypeptide in a therapeutically effective amount.

123. - 138. (Cancelled)

139. (Previously Presented) The method of claim 121, wherein said RTEF-1 polypeptide has at least 95% sequence identity to the sequence of SEQ ID NO:7.

140. (Previously Presented) The method of claim 139, wherein said RTEF-1 polypeptide comprises the sequence of SEQ ID NO:7.

141.-143. (Cancelled)

144. (Previously Presented) The method of claim 120, wherein said tissue is ischemic or hypoxic.

145. (Cancelled)